PATENT CLAIM ANALYSIS

Application Number: 15868567
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.

Claim (Index 1):
A pharmaceutical formulation comprising:\n (a) a chimeric or humanized version of antibody 2A4 (ATCC Accession Number PTA-9662) or of antibody 7D8 (ATCC Accession Number PTA-9468), or fragment thereof, that specifically competes for binding to antigen with 2A4 or 7D8, wherein the antibody is present at a concentration within the range from about 1 mg/mL to about 100 mg/mL; (b) histidine buffer present at a concentration within the range from about 20 mM to about 30 mM; (c) trehalose present at a concentration within the range from about 210 mM to about 250 mM; and (d) polysorbate 20 present at a concentration within the range from about 0.005% to about 0.05% by weight; wherein the formulation is characterized by a pH within the range from about 6 to about 7.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 86.0
- Lexical Diversity: 1.1875
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13660957', '13187093', '12345650', '13314160', '12811049']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7797491897883727
- 35 USC 102 Novelty (BERT): 0.5909723689015524
- Combined Prediction Score: 0.7608715076996907
- Mean Citation Score: 433.22061
- Max Citation Score: 545.3246
- Similarity Product: 436.8455039132595

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test